Clinical Trial Update: Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone

View source ↗

Summary

Pfizer-sponsored post-marketing surveillance in Korea evaluating Ngenla pre-filled pen for pediatric growth disturbance due to growth hormone deficiency; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• NGENLA (SOMATROGON-GHLA)

Snippet

Sponsor: Pfizer | Conditions: Pediatric Growth Hormone Deficiency | Status: ACTIVE_NOT_RECRUITING